Allergen-specific immunotherapy for atopic dermatitis: current status, problems and prospects



Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Atopic dermatitis is one of the most common diseases (accounting for 20% to 40% of the structure of skin diseases) and occurs in all countries, in individuals of both sexes and across different age groups. The disease can significantly reduce quality of life, including serving as a cause of social maladaptation; therefore, the issue of studying effective methods for the treatment of atopic dermatitis remains relevant, aimed at minimizing its manifestations and prolonging periods of remission. The key components of the pathogenesis of atopic dermatitis are impairment of the skin barrier function, chronic T2- inflammation, and the development of IgE-specific sensitization to various allergens. Along with allergic rhinitis and bronchial asthma, atopic dermatitis belongs to T2-associated diseases, for which one of the treatment options is allergen-specific immunotherapy. This method has proven successful in the treatment of atopic diseases and, due to its disease-modifying effect, the issue of its efficacy and safety in patients with atopic dermatitis has been actively studied in recent years.

This review summarizes current data on the use of allergen-specific immunotherapy with house dust mite allergens in patients with atopic dermatitis.

Full Text

Restricted Access

About the authors

Valeriia Iuzhaninova

Государственный научный центр «Институт иммунологии»

Email: qwwvl1@yandex.ru
ORCID iD: 0009-0009-6943-947X
Russian Federation, Москва

Olga G. Elisyutina

National Research Center – Institute of Immunology Federal Medico-Biological Agency; Peoples’ Friendship University of Russia

Email: el-olga@yandex.ru
ORCID iD: 0000-0002-4609-2591
SPIN-code: 9567-1894

MD, Dr. Sci (Medicine)

Russian Federation, Moscow; Moscow

Evgeniy V. Smolnikov

National Research Center – Institute of Immunology Federal Medico-Biological Agency; Peoples’ Friendship University of Russia

Email: qweril2010@yandex.ru
ORCID iD: 0000-0003-1302-4178
SPIN-code: 4874-8100

MD

Russian Federation, Moscow; Moscow

Elena S. Fedenko

National Research Center – Institute of Immunology Federal Medico-Biological Agency

Author for correspondence.
Email: efedks@gmail.com
ORCID iD: 0000-0003-3358-5087
SPIN-code: 5012-7242

MD, Dr. Sci. (Medicine), Professor

Russian Federation, Moscow

Natalya I. Ilyina

National Research Center — Institute of Immunology Federal Medical-Biological Agency; The Russian National Research Medical University named after N.I. Pirogov

Email: instimmun@yandex.ru
ORCID iD: 0000-0002-3556-969X
SPIN-code: 6715-5650

MD, Dr. Sci. (Medicine), Professor

Russian Federation, Moscow; Moscow

Dina V. Kleiner

Stallergenes Vostok LLC

Email: kleiner.dina@gmail.com
ORCID iD: 0009-0005-2103-6234

MD, Cand. Sci. (Medicine)

Russian Federation, Moscow

References

  1. Атопический дерматит. Клинические рекомендации. Российская ассоциация аллергологов и клинических иммунологов, Союз педиатров России, Общероссийская общественная организация "Российское общество дерматовенерологов и косметологов", Общероссийская общественная организация "Национальный альянс дерматовенерологов и косметологов". 2024. Режим доступа: https://cr.minzdrav.gov.ru/view-cr/265_3. Дата обращения: 27.01.2026.
  2. Laughter MR, Maymone MBC, Mashayekhi S, et al. The global burden of atopic dermatitis: lessons from the Global Burden of Disease Study 1990–2017. Br J Dermatol. 2020;184(2):304-309. doi: 10.1111/bjd.19580. EDN: RDYCJD.
  3. Shin YH, Hwang J, Kwon R, et al. Global, regional, and national burden of allergic disorders and their risk factors in 204 countries and territories, from 1990 to 2019: a systematic analysis for the Global Burden of Disease Study 2019. Allergy. 2023;78(8):2232-2254. doi: 10.1111/all.15807. EDN: PNFVLS.
  4. Bogacz-Piaseczyńska A, Bożek A. Allergen immunotherapy in atopic dermatitis. Alergologia Polska - Polish Journal of Allergology. 2024;11(3):257-263. doi: 10.5114/pja.2024.142500. EDN: CNQXDO.
  5. Guttman-Yassky E, Renert-Yuval Y, Brunner PM. Atopic dermatitis. Lancet. 2025;405(10478):583-596. doi: 10.1016/S0140-6736(24)02519-4. EDN: HBAMDW.
  6. Pessina B, Giovannini M, Mori F, et al. Is there room for allergen immunotherapy for the treatment of atopic dermatitis in the precision medicine era? Front Pediatr. 2022;10:1050560. doi: 10.3389/fped.2022.1050560. EDN: RHATFN.
  7. Bai R, Zheng Y, Dai X. Atopic dermatitis: diagnosis, molecular pathogenesis, and therapeutics. Mol Biomed. 2025;6(1):71. doi: 10.1186/s43556-025-00313-3. EDN: ZWURNC.
  8. Park CO, Kim SM, Lee KH, Bieber T. Biomarkers for phenotype-endotype relationship in atopic dermatitis: a critical review. EBioMedicine. 2024;103:105121. doi: 10.1016/j.ebiom.2024.105121.
  9. Ohya Y. Prevention of atopic dermatitis: what are we missing? Allergy Asthma Immunol Res. 2025;17(4):433-446. doi: 10.4168/aair.2025.17.4.433. EDN: UNWODD.
  10. Wollenberg A, Kinberger M, Arents B, et al. European guideline (EuroGuiDerm) on atopic eczema–part II: non-systemic treatments and treatment recommendations for special AE patient populations. J Eur Acad Dermatol Venereol. 2022;36(10):1904-1926. doi: 10.1111/jdv.18429.
  11. Saeki H, Ohya Y, Furuta J, et al; Committee for Clinical Practice Guidelines for the Management of Atopic Dermatitis 2021, The Japanese Society of Allergology, The Japanese Dermatology Association. Executive summary: Japanese guidelines for atopic dermatitis (ADGL) 2021. Allergol Int. 2022;71(4):448-458. doi: 10.1016/j.alit.2022.06.009. EDN: EHBjde.
  12. Eichenfield LF, Tom WL, Berger TG, et al. Guidelines of care for the management of atopic dermatitis: section 2. Management and treatment of atopic dermatitis with topical therapies. J Am Acad Dermatol. 2014;71(1):116-132. doi: 10.1016/j.jaad.2014.03.023.
  13. Wollenberg A, Kinberger M, Arents B, et al. European guideline (EuroGuiDerm) on atopic eczema: part I–systemic therapy. J Eur Acad Dermatol Venereol. 2022;36(9):1409-1431. doi: 10.1111/jdv.18345. EDN: HYTUSX.
  14. Sidbury R, Davis DM, Cohen DE, et al. Guidelines of care for the management of atopic dermatitis: section 3. Management and treatment with phototherapy and systemic agents. J Am Acad Dermatol. 2014;71(2):327-349. doi: 10.1016/j.jaad.2014.03.030.
  15. Kim DH, Choi E, Lee JS, et al. House dust mite allergen regulates constitutive apoptosis of normal and asthmatic neutrophils via Toll-like receptor 4. PLoS One. 2015;10(5):e0125983. doi: 10.1371/journal.pone.0125983.
  16. Czarnowicki T, Krueger JG, Guttman-Yassky E. Novel concepts of prevention and treatment of atopic dermatitis through barrier and immune manipulations with implications for the atopic march. J Allergy Clin Immunol. 2017;139(6):1723-1734. doi: 10.1016/j.jaci.2017.04.004.
  17. Huang HJ, Sarzsinszky E, Vrtala S. House dust mite allergy: the importance of house dust mite allergens for diagnosis and immunotherapy. Mol Immunol. 2023;158:54-67. doi: 10.1016/j.molimm.2023.04.008.
  18. Itamura M, Sawada Y. Involvement of atopic dermatitis in the development of systemic inflammatory diseases. Int J Mol Sci. 2022;23(21):13445. doi: 10.3390/ijms232113445. EDN: EDYYBU.
  19. Elisyutina OG, Litovkina AO, Smolnikov EV, Fedenko ES. The experience with subcutaneous allergen-specific immunotherapy with pollen allergens in patients with atopic dermatitis. Russian Journal of Allergy. 2024;21(1):17-28. doi: 10.36691/RJA16911. EDN: LTBGFD
  20. Bumbacea RS, Corcea SL, Ali S, et al. Mite allergy and atopic dermatitis: is there a clear link? (Review). Exp Ther Med. 2020;20(6):3554-3560. doi: 10.3892/etm.2020.9120. EDN: HIXQQK.
  21. Compalati E, Rogkakou A, Passalacqua G, Canonica GW. Evidences of efficacy of allergen immunotherapy in atopic dermatitis: an updated review. Curr Opin Allergy Clin Immunol. 2012;12(4):427-433. doi: 10.1097/ACI.0b013e328354e540.
  22. Guo B-C, Wu K-H, Chen C-Y, et al. Advancements in allergen immunotherapy for the treatment of atopic dermatitis. Int J Mol Sci. 2024;25(2):1316. doi: 10.3390/ijms25021316. EDN: PGQWPU.
  23. Shtyrbul OV, Dvornikov AS, Khaitov MR, et al. Molecular allergodiagnostics capabilities in determining the indications for allergen-specific immunotherapy with house dust mites allergen and its effectiveness in atopic dermatitis patients. Russian Journal of Allergy. 2020;17(3):82-92. doi: 10.36691/RJA1389. EDN: GHNUIZ.
  24. Huang HJ, Sarzsinszky E, Vrtala S. House dust mite allergy: the importance of house dust mite allergens for diagnosis and immunotherapy. Mol Immunol. 2023;158:54-67. doi: 10.1016/j.molimm.2023.04.008. EDN: GEGLFV.
  25. Calderón MA, Linneberg A, Kleine-Tebbe J, et al. Respiratory allergy caused by house dust mites: what do we really know? J Allergy Clin Immunol. 2015;136(1):38-48. doi: 10.1016/j.jaci.2014.10.012. EDN: URSUSV.
  26. Kita H. How are airborne allergens remembered by the immune system? J Allergy Clin Immunol. 2022;149(6):1940-1942. doi: 10.1016/j.jaci.2022.02.014. EDN: DDYOZN.
  27. Kim DH, Choi E, Lee JS, et al. House dust mite allergen regulates constitutive apoptosis of normal and asthmatic neutrophils via Toll-like receptor 4. PLoS One. 2015;10(5):e0125983. doi: 10.1371/journal.pone.0125983.
  28. Barry J, Loh Z, Collison A, et al. Absence of Toll–IL-1 receptor 8/single immunoglobulin IL-1 receptor–related molecule reduces house dust mite–induced allergic airway inflammation in mice. Am J Respir Cell Mol Biol. 2013;49(4):481-490.
  29. Vrtala S. Allergens from house dust and storage mites. Allergo J Int. 2022;31(5):267-271. doi: 10.1007/s40629-022-00226-5. EDN: MATWAY.
  30. Smolnikov EV, Litovkina AO, Kolykhalova KI, Elisyutina OG, Fedenko ES. The role of atopy patch test with aeroallergens in allergic diseases diagnostics. Russian Journal of Allergy. 2021;17(4):30-37. doi: 10.36691/RJA1355. EDN: HXCCPO.
  31. Ring J, Kunz B, Bieber T, et al. The "atopy patch test" with aeroallergens in atopic eczema (Abstr.). J Allergy Clin Immunol. 1989;82(1):195.
  32. Gutermuth J, Grosber M, Pfaar O, Bergmann KC, Ring J. 111 years of allergen-immunotherapy: a long and successful history of the only available disease-modifier in allergic diseases. Allergol Select. 2022;6:248-258. doi: 10.5414/ALX02330E. EDN: KYRCUO.
  33. Cox L, Nelson H, Lockey R, et al. Allergen immunotherapy: a practice parameter third update. J Allergy Clin Immunol. 2011;127(1 Suppl):S1-55. doi: 10.1016/j.jaci.2010.09.034.
  34. Bumbacea RS, Boustani R, Panaitescu C, et al. Mechanisms of allergen immunotherapy supporting its disease-modifying effect. Immunotherapy. 2022;14(8):627-638. doi: 10.2217/imt-2021-0325. EDN: JIIXDV.
  35. Yepes-Nuñez JJ, Guyatt GH, Gómez-Escobar LG, et al. Allergen immunotherapy for atopic dermatitis: systematic review and meta-analysis of benefits and harms. J Allergy Clin Immunol. 2023;151(1):147-158. doi: 10.1016/j.jaci.2022.09.020. EDN: LCXFIQ.
  36. Cox L. Allergen immunotherapy: immunomodulatory treatment for allergic diseases. Expert Rev Clin Immunol. 2006;2(4):533-546. doi: 10.1586/1744666X.2.4.533.
  37. Akdis CA, Akdis M. Advances in allergen immunotherapy: aiming for complete tolerance to allergens. Sci Transl Med. 2015;7(280):280ps6. doi: 10.1126/scitranslmed.aaa7390.
  38. Han H, Roan F, Ziegler SF. The atopic march: current insights into skin barrier dysfunction and epithelial cell-derived cytokines. Immunol Rev. 2017;278(1):116-130. doi: 10.1111/imr.12546. EDN: YFHASQ.
  39. Kaufman HS, Roth HL. Hyposensitization with alum precipitated extracts in atopic dermatitis: a placebo-controlled study. Ann Allergy. 1974;32(6):321-330. PMID: 4597822.
  40. Mastrandrea F. Immunotherapy in atopic dermatitis. Expert Opin Investig Drugs. 2001;10(1):49-63. doi: 10.1517/13543784.10.1.49.
  41. Warner JO, Price JF, Soothill JF, Hey EN. Controlled trial of hyposensitisation to Dermatophagoides pteronyssinus in children with asthma. Lancet. 1978;2(8096):912-915. doi: 10.1016/S0140-6736(78)91630-6.
  42. Pajno GB, Caminiti L, Vita D, et al. Sublingual immunotherapy in mite-sensitized children with atopic dermatitis: a randomized, double-blind, placebo-controlled study. J Allergy Clin Immunol. 2007;120(1):164-170. doi: 10.1016/j.jaci.2007.04.008. EDN: MAGVRD.
  43. Caminiti L, Panasiti I, Landi M, et al. Allergen immunotherapy in atopic dermatitis: light and shadow in children. Pediatr Allergy Immunol. 2020;31 Suppl 26:46-48. doi: 10.1111/pai.13390. EDN: PRBIYW.
  44. Bae JM, Choi YY, Park CO, Chung KY, Lee KH. Efficacy of allergen-specific immunotherapy for atopic dermatitis: a systematic review and meta-analysis of randomized controlled trials. J Allergy Clin Immunol. 2013;132(1):110-117. doi: 10.1016/j.jaci.2013.02.044.
  45. Traidl S, Werfel T. Allergenimmuntherapie bei atopischer Dermatitis. Hautarzt. 2021;72(12):1103-1112. doi: 10.1007/s00105-021-04909-y. EDN: ANFPOA.
  46. Shamji MH, Durham SR. Mechanisms of allergen immunotherapy for inhaled allergens and predictive biomarkers. J Allergy Clin Immunol. 2017;140(6):1485-1498. doi: 10.1016/j.jaci.2017.10.010.
  47. Golebski K, Layhadi JA, Sahiner U, et al. Induction of IL-10-producing type 2 innate lymphoid cells by allergen immunotherapy is associated with clinical response. Immunity. 2021;54(2):291-307.e7. doi: 10.1016/j.immuni.2020.12.013.
  48. Werfel T, Heratizadeh A, Niebuhr M, et al. Exacerbation of atopic dermatitis on grass pollen exposure in an environmental challenge chamber. J Allergy Clin Immunol. 2015;136(1):96-103.e9. doi: 10.1016/j.jaci.2015.04.015.
  49. Kim J, Boo J, Jang H, et al. Combined dupilumab and allergen-specific immunotherapy in severe refractory atopic dermatitis. Allergy Asthma Immunol Res. 2024;16(6):682-689. doi: 10.4168/aair.2024.16.6.682.
  50. Liu J, Yang L, Xu Q, et al. Allergen immunotherapy and dupilumab in atopic dermatitis: clinical efficacy and disparities in immunological indicators. World Allergy Organ J. 2025;18(3):101043. doi: 10.1016/j.waojou.2025.101043. EDN: RUXOMC.
  51. Bogacz-Piaseczyńska A, Bożek A, Krupka-Olek M, et al. Dupilumab and house dust mite immunotherapy in patients with atopic dermatitis: a preliminary study. Vaccines (Basel). 2024;12(9):1046. doi: 10.3390/vaccines12091046.
  52. Елисютина ОГ, Феденко ЕС. Место специфической иммунотерапии в лечении больных атопическим дерматитом, осложненным рецидивирующей пиодермией. Физиология и патология иммунной системы. 2006;(8):15-20.
  53. Elisyutina O, Fedenko E. Specific immunotherapy in atopic dermatitis with staphylococcal and house dust mite allergovaccines. Allergy. 2007;62(Suppl 83):92.
  54. Slavyanskaya TA, Derkach VV, Sepiashvili RI. Modern approaches to specific immunotherapy in atopic dermatitis children. Russian Journal of Allergy. 2015;12(5):31-38. doi: 10.36691/RJA431. EDN: VLMLGX.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright © ABV-press,

License URL: https://rusalljournal.ru/raj/about/submissions#copyrightNotice
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77-42773 от  21.07.2009.